DCC-2618 ID:563
| Synonyms: |
| CAS NO : 1225278-16-9 |
|
| Molecular Formula: C26H21F2N5O3 |
| Molecular Weight: 489.47 |
| Purity: 98% min |
| Solubility: In DMSO |
| Storage: -20°C |
Availability and Price
| |
If the item is temporarily out of stock. Please email to sales@betterbiochem.com,we will inform you when we have it in stock. |
| In Stock |
| |
 Order |
Remarks:Description: IC50 Value: 6 nM and 9 nM for wt c-KIT and KIT V654A exon 13 respectively; 30 nM and 13 nM for PDGFR alpha and beta respectively [1]. DCC-2618 has been designed to effectively inhibit the imatinib and sunitinib-sensitive KIT juxtamembrane domain mutants (JMD) as well as secondary resistant KIT kinase-domain mutants. DCC-2618 additionally targets PDGFR alpha oncogenic mutants [1]. Deciphera's technology has identified DCC-2618 as a molecule which can be developed as second line therapy for imatinib and sunitinib resistant GIST patients with the potential to progress to frontline GIST therapy. in vitro: DCC-2618 inhibits normal and mutant KIT kinase at the nanomol level. The targets are wt c-KIT, c-KIT mutants, PDGFR alpha, PDGFR beta, KDR and cFMS. DCC-2618 inhibits mutant KIT in GIST patient cell line (GIST T1 pKIT western Ex11 deletion) at a IC 50 of 2 nM [1].
Quality Control
Quality Control by H-NMR,C-NMR,LC-MS,HPLC. |
|
Related Products
 c-Kit // c-Met |
